116 related articles for article (PubMed ID: 21881834)
1. Sunitinib and Thrombosis.
Lamba G; Deol R; Shah D; Sahni R; Malhotra BK
J Gastrointest Cancer; 2012 Sep; 43 Suppl 1():S128-30. PubMed ID: 21881834
[No Abstract] [Full Text] [Related]
2. Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib.
Saylor PJ; Reid TR
J Clin Oncol; 2007 Aug; 25(23):3544-6. PubMed ID: 17687160
[No Abstract] [Full Text] [Related]
3. Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors.
Lee NR; Yhim HY; Yim CY; Kwak JY; Song EK
Ann Pharmacother; 2011 Oct; 45(10):e56. PubMed ID: 21954449
[TBL] [Abstract][Full Text] [Related]
4. Acute severe hypothyroidism induced by sunitinib.
Prat A; Serrano C; Valverde C; Calvo E
Radiother Oncol; 2008 Oct; 89(1):124-5. PubMed ID: 18502526
[No Abstract] [Full Text] [Related]
5. Successful treatment with sunitinib in a young patient with metastatic gastrointestinal stromal tumor after failure on adjuvant imatinib.
Kapoor R; Khosla D; Kumar P; Kumar N; Bera A
J Cancer Res Ther; 2011; 7(4):491-3. PubMed ID: 22269418
[No Abstract] [Full Text] [Related]
6. Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options.
Caram MV; Schuetze SM
J Surg Oncol; 2011 Dec; 104(8):888-95. PubMed ID: 22069173
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib-induced reversible purpuric rash in a patient with gastrointestinal stromal tumor.
Mutlu H; Büyükçelik A; Akça Z; Kaya N
J Oncol Pharm Pract; 2014 Aug; 20(4):298-301. PubMed ID: 23929730
[TBL] [Abstract][Full Text] [Related]
8. Transient sunitinib resistance in gastrointestinal stromal tumors.
Bracci R; Maccaroni E; Cascinu S
N Engl J Med; 2013 May; 368(21):2042-3. PubMed ID: 23697529
[No Abstract] [Full Text] [Related]
9. Cardiotoxicity associated with sunitinib.
Hariharan S; Lowry S
Lancet; 2008 Apr; 371(9620):1244-5; author reply 1245. PubMed ID: 18406854
[No Abstract] [Full Text] [Related]
10. Efficacy of sunitinib in Turkish patients with gastrointestinal stromal tumors; retrospective multicenter experience.
Kefeli U; Buyuberber S; Akyol M; Yildiz R; Kaplan MA; Ciltas A; Sevinc A; Karaca H; Seker M; Ozdemir N; Alacacioglu A; Coskun U; Isikdogan A; Dane F; Gumus M; Ozkan M; Suner A; Tarhan MO; Benekli M
Hepatogastroenterology; 2013 Jun; 60(124):647-52. PubMed ID: 23165189
[TBL] [Abstract][Full Text] [Related]
11. Pyoderma gangrenosum: another cutaneous side-effect of sunitinib?
ten Freyhaus K; Homey B; Bieber T; Wilsmann-Theis D
Br J Dermatol; 2008 Jul; 159(1):242-3. PubMed ID: 18489600
[No Abstract] [Full Text] [Related]
12. Sunitinib-induced pseudoporphyria.
Sanz-Motilva V; Martorell-Calatayud A; Llombart B; Requena C; Serra-Guillén C; Nagore E; Guillén C; Traves V; Sanmartín O
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1848-50. PubMed ID: 24813651
[No Abstract] [Full Text] [Related]
13. Summaries for patients. Underactive thyroid function after treatment with sunitinib for gastrointestinal cancer.
Ann Intern Med; 2006 Nov; 145(9):I44. PubMed ID: 17088575
[No Abstract] [Full Text] [Related]
14. [Drug Interaction between Sutent (sunitinib) and Bi-spirogyl (spiramycin-metronidazol): risk of toxicity].
Trabelsi S; Boussen H; Gaïes E; Salouage I; El Aïdli S; Daghfous R; Loueslati MH; Lakhal M; Belkahia C
Therapie; 2008; 63(6):475-6. PubMed ID: 19374036
[No Abstract] [Full Text] [Related]
15. Guillain-Barré syndrome after treatment with sunitinib malate?
Mulherin B; Loconte NK; Holen KD
Oncology (Williston Park); 2008 Jan; 22(1):66-7, 70-1. PubMed ID: 18251284
[TBL] [Abstract][Full Text] [Related]
16. [Chemotherapy and target-therapy of gastrointestinal tumors call for development of pathology].
Shen L
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):438-9. PubMed ID: 17845753
[No Abstract] [Full Text] [Related]
17. Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor.
Turan N; Benekli M; Ozturk SC; Inal S; Memis L; Guz G; Cetin B; Buyukberber S
Ann Pharmacother; 2012 Oct; 46(10):e27. PubMed ID: 23032654
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and safety of sunitinib after imatinib failure in Japanese patients with gastrointestinal stromal tumor.
Matsumoto K; Sawaki A; Mizuno N; Hara K; Hijioka S; Niwa Y; Tajika M; Kawai H; Kondo S; Yamao K
Jpn J Clin Oncol; 2011 Jan; 41(1):57-62. PubMed ID: 20858619
[TBL] [Abstract][Full Text] [Related]
19. Impaired coronary flow reserve in metastatic cancer patients treated with sunitinib.
Sen F; Yildiz I; Basaran M; Ekenel M; Oz F; Kilic L; Toz B; Gurdal A; Camlica H; Bavbek S; Oflaz H
J BUON; 2013; 18(3):775-81. PubMed ID: 24065498
[TBL] [Abstract][Full Text] [Related]
20. Imatinib-induced interstitial lung disease and sunitinib-associated intra-tumour haemorrhage.
Loong HH; Yeo W
Hong Kong Med J; 2008 Dec; 14(6):495-8. PubMed ID: 19060352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
